MPLT
MPLT
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
6
$1.06M
Total Volume
$1.06M
23 transactions
Net Activity
$1.06M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale Insiders
$3515.02B total
Kroeger Christopher A.
CEO
$595K total
Foff Erin Pennock
Chief Medical Officer
$124K total
Kreitzer Anatol
Chief Discovery Officer
$96K total
Lillie James Woodruff
Chief Scientific Officer
$93K total
Quick Actions
MPLT has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at MPLT (MPLT) engaged in a total of 23 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 6 were sales. The total volume of insider trading reached $1.06M.
The net insider activity for MPLT shows a net selling bias of $1.06M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 3.69M shares valued at $3513.13B on Oct 28, 2025.
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?
A $463 million cash position is expected to back MapLight’s planned and ongoing drug trials through 2028.
Should I buy MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ)
MPLT - MapLight Therapeutics Inc Stock Price and Quote
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Reaffirmed as Buy by Canaccord Genuity Group
FAQs About MPLT Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for MPLT.